Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-Cell lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 2, 2010, Pages 118-124

  Troutaud, Danielle ^a   Petit, Barbara ^a,b   Bellanger, Cynthia ^a   Marin, Benoît ^a,b   Gourin Chaury, Marie Pierre ^b   Petit, Daniel ^a   Olivrie, Agnés ^b   Feuillard, Jean ^a,b   Jauberteau, Marie Odile ^a   Bordessoule, Dominique ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

BCL 2; CHOP; Clinical stages; Non Hodgkin lymphoma; PP1

Indexed keywords

APOPTOSIS INDUCING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; PHOSPHOPROTEIN PHOSPHATASE 1; PREDNISONE; PROTEIN BAD; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZOYLAMIDO 4' AMINOSTILBENE 2,2' DISULFONATE; BENZOYLAMIDO-4'-AMINOSTILBENE-2,2'-DISULFONATE; CHOP PROTOCOL; MONOCLONAL ANTIBODY; STILBENE DERIVATIVE;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MALE; MITOCHONDRION; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; RETROSPECTIVE STUDY; B CELL LYMPHOMA; B LYMPHOCYTE; CHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; STILBENES; VINCRISTINE;

EID: 77954668224     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.016     Document Type: Article

References (34)

1. A clinical evaluation of the International Lymphoma Study Group classification of non Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-18.
2. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-Cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
3. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714-23.
4. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13:325-34.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-Cell lymphoma. N Engl J Med 2002; 346: 235-42.
6. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-Cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33.
7. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-Cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
8. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-Cell lymphoma (DLBCL). Blood 2003; 101:4279-84.
9. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of im-munohistochemically defined germinal center phenotype in diffuse l arge B-Cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-5.
10. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-Cell lymphoma. Leuk Lymphoma 2007; 48: 1102-9.
11. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-Cell-like and non-germinal center B-Cell-like subtypes of diffuse large B-Cell lymphoma. J Clin Oncol 2008; 26: 4587-94.
12. Juin P, Geneste O, Raimbaud E, et al. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta 2004; 1644: 251-60.
13. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies.Blood 2005; 106: 408-18.
14. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 589-92.
15. Datta SR, Katsov A, Hu L, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 2000; 6: 41-51.
16. Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002; 3: 631-43.
17. Malissein E, Verdier M, Ratinaud MH, et al. Activation of Bad trafficking is involved in the BCR-mediated apoptosis of immature B cells. Apoptosis 2006; 11: 1003-12.
18. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-Cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131-8.
19. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-Cell lymphoma. Blood 2002; 99: 1136-43.
20. Ranger AM, Zha J, Harada H, et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9324-9.
21. Xerri L, Devilard E, Bouabdallah R, et al. Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin's lymphomas. Leukemia 1999; 13: 1548-53.
22. Ayllón V, Martinez-A C, Garcia A, et al. Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates IL-2 deprivation-induced apoptosis.EMBO J 2000; 19: 2237-46.
23. Fleischer A, Ghadiri A, Dessauge F, et al. Bad-dependent rafts alteration is a consequence of an early intracellular signal triggered by interleukin-4 deprivation. Mol Cancer Res 2004; 2: 674-84.
24. Lorenzo HK, Susin SA, Penninger J, et al. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 1999; 6: 516-24.
25. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mito-chondrial apoptosis-inducing factor. Nature 1999; 397: 441-6.
26. Modjtahedi N, Giordanetto F, Madeo F, et al. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol 2006; 16: 264-72.
27. Porter AG, Urbano AG. Does apoptosis-inducing factor (AIF) have both life and death functions in cells? Bioessays 2006; 28: 834-43.
28. Urbano A, Lakshmanan U, Choo PH, et al. AIF suppresses chemical stressinduced apoptosis and maintains the transformed state of tumor cells. EMBO J 2005; 24: 2815-26.
29. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-61.
30. Kitada S, Krajewska M, Zhang X, et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 152: 51-61.
31. Bai M, Skyrlas A, Agnantis NK, et al. Diffuse large B-Cell lymphomas with germinal center B-Cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol 2004;17: 847-56.
32. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-Cell-like type of diffuse large B-Cell lymphoma. J Clin Oncol 2006;24: 961-8.
33. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-Cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
34. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma. N Engl J Med 2002; 346:1937-47.